Puma Biotechnology
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 185
- Market Cap
- $124.5M
- Introduction
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Conditions
- Metastatic Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerRecurrent Breast Cancer
- Interventions
- Drug: Endocrine therapy
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06369285
- Locations
- 🇪🇸
Fundación Instituto Valenciano de OncologÃa (IVO), Valencia, Spain
🇺🇸Alabama Oncology, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Hospital, Phoenix, Arizona, United States
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06095505
- Locations
- 🇺🇸
Southern Cancer Center, Daphne, Alabama, United States
🇺🇸The Oncology Institute of Hope and Innovation, Fort Lauderdale, Florida, United States
🇺🇸Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States
A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib
- Conditions
- HER2 Amplified Breast Cancer
- Interventions
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04366713
- Locations
- 🇵🇹
Hospital CUF Descobertas, Lisboa, Portugal
HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib
- Conditions
- Metastatic Cervical CancerHormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 1583
- Registration Number
- NCT03786107
- Locations
- 🇷🇸
Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
🇺🇸Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
🇫🇷Institut Curie, Saint-Cloud, France
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
- Conditions
- Early Stage HER2+ Breast Cancer
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 563
- Registration Number
- NCT02400476
- Locations
- 🇺🇸
Compassionate Care Research Group Inc., Riverside, California, United States
🇺🇸Emad Ibrahim, M.D., Inc., Redlands, California, United States
🇺🇸The Oncology Institute of Hope and Innovation, Santa Ana, California, United States
Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02334501
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
- Conditions
- Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
- Interventions
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 582
- Registration Number
- NCT01953926
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇮🇹Istituto Europeo di Oncologia (IEO) I.R.C.C.S., Milano, Italy
🇺🇸Gundersen Center for Cancer and Blood Disorders, La Crosse, Wisconsin, United States
Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer
- Conditions
- HER2-mutant Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT01827267
- Locations
- 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
- Conditions
- HER2+ Metastatic Breast Cancer (MBC)
- Interventions
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 621
- Registration Number
- NCT01808573
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸University of California San Diego Medical Center - Hillcrest, San Diego, California, United States
🇺🇸Sharp Memorial Hospital, San Diego, California, United States
A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT01142063
- Locations
- 🇺🇸
Investigational Site, New Haven, Connecticut, United States